Arbutus Biopharma Corporation (ABUS)

[urche]

I am new to this board, even though I have followed the company even when it was Tekmira.
Glad to see Dew hanging out here!

I am curious what theories we have about why the sudden spike in volume, seemingly on no news since the disappointing trial results about a month ago. My own theory is that the activity starting at the open yesterday is related to sales data released by Alnyam. As I recall, ABUS gets royalties from Onpattro and maybe another Alnyam drug.
Here is snip from the Alnyam PR this week:
For the rest of the year and beyond, we expect steady and continued growth in patients on ONPATTRO therapy through improved disease awareness, new patient finding, expansion in global markets – such as our recent launch in Japan and NDA filing in Brazil – and the potential for future label expansion in hereditary and wild-type ATTR cardiomyopathy through our recently initiated APOLLO-B Phase 3 study. We’re also pleased to have received a Priority Review and Accelerated Assessment for givosiran from the FDA and EMA, respectively, and we are preparing for the potential launch of our second RNAi therapeutic in the coming months, assuming positive regulatory reviews,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam.

Other theories?